Method: WF-IMRT technique consisted of a single IMRT plan including the primary tumor, the superior and inferior neck to the level of the clavicular heads. The larynx was defined as an organ at risk extending superiorly to cover the arythenoid cartilages and inferiorly to include the crycoid cartilage. The J-IMRT technique consisted of an IMRT plan for the primary tumor and the superior neck, matched to a conventional antero-posterior opposing lower neck fields at the level of the thyroid notch. A central block was used for the anterior lower neck field at the level of the larynx in order to restrict the dose to the larynx. Ten oropharyngeal cancer cases were analyzed. Both the primary site and bilateral regional lymphatics were included in the radiotherapy targets.
Results: The averaged V95 for the PTV57.6 was 99.2% for WF-IMRT technique when compared with 97.4% (p=0.02) for J-IMRT. The averaged V95 for the PTV64 was 99.9% for WF-IMRT technique when compared with 98.9% (p=0.02) for J-IMRT and the averaged V95 for the PT70 was 100.0% for WF-IMRT technique when compared with 99.5% (p=0.04) for J-IMRT.
The averaged mean laryngeal dose was 18 Gy with both techniques. The averaged mean dose within the matchline volumes were 69.3Gy for WF-MRT vs 66.2 Gy for J-IMRT (p=0.03).
Conclusion: WF-IMRT technique appears to offer an optimal coverage of the target volumes and a mean dose to the larynx similar with J-IMRT and should be further evaluated in clinical trials.
INTRODUCTION
The optimal management of oropharyngeal cancer is multidisciplinary and radiotherapy is a part of treatment approach for most of these patients. The greatest challenge with radiotherapy for oropharyngeal cancer is to maximize loco-regional disease control, while minimizing the morbidity and treatment-related toxicity to surrounding normal tissues, including the larynx [1] .
With the development of the Intensity-Modulated Radiation Therapy (IMRT) technique, head and neck cancers have been treated with good results as reported by various investigators [2, 3] .
IMRT has been shown to offer better target homogeneity and tumor coverage and normal organ sparing [3, 4] . However, the use of IMRT tends to unnecessarily deliver higher dose to the larynx [5] . More than one decade ago, Mendenhall et al. discouraged the practice of including the uninvolved larynx in the radiation fields when the non-laryngeal primary tumor site could be adequately covered by placing the inferior border of the opposed lateral fields at the level of the thyroid notch. The superior section of the plan was matched to a conventional anterior neck field resulting in very low doses to the larynx, which was typically blocked on the anterior field [1] .
Emerging data from patients with long term follow up have showed that irradiation of the normal larynx is associated with laryngeal dysfunction affecting patients' quality of life in head and neck cancer survivors, treated with radiation therapy [6, 7] . Furthermore, recent studies by Eisburch et al. have shown that sparing larynx improves dysphagia and aspiration [8] .
The current study was undertaken to determine if the laryngeal dose can be reduced when using IMRT techniques including the attempt to spare the larynx based on given dose constraints for this organ at risk when a whole-neck field IMRT (WF-IMRT) is chosen or the use of a junctioned IMRT (J-IMRT) consisting of an IMRT plan for the primary non-laryngeal tumor and the superior neck, matched with a conventional opposed antero-posterior lower neck fields at the level of the thyroid notch.
MATERIALS & METHODS

Patient Selection
Ten consecutive patients diagnosed with stage IV oropharyngeal squamous cell carcinoma and treated between September 2006 and January 2007, at the University of Pennsylvania, Department of Radiation Oncology were included in the current study. Approval was granted by the Institutional Review Board for conducting this study. Nine patients were diagnosed with stage IV A disease (T1-3N2bM0) and one patient with stage IV B disease (T2N3M0). The nodal disease at the neck in four cases extended inferiorly to the level of the glottic larynx. All patients were treated with IMRT to the primary site and the bilateral cervical lymph nodes. Two treatment plans were generated for each patient using WF-IMRT and J-IMRT techniques and the dosimetric data was compared between the two treatment plans. The coverage of the target volumes and the dose to the larynx were compared using the resulting dose volume histograms and the following dose parameters: V100 and V95 for the targets, and mean laryngeal dose. V100 was defined as the percent of the target volume covered by 100% of the prescribed dose and V95 was defined as the percent of the target volume covered by 95% of the prescribed dose.
Radiotherapy treatment planning
All patients underwent a CT-based planning for IMRT using a 3 mm CT slice thickness to cover the oropharyngeal tumors and bilateral cervical lymph nodes. Gross tumor volume (GTV) was defined as the grossly visible tumor and metastatic lymphadenopathy on physical examination and imaging studies (contrast CT and/or MRI). Clinical target volume (CTV1) encompassed the GTV and the adjacent tissue supposed to contain microscopic, subclinical tumor extension and first echelon nodes. The uninvolved nodal areas that were at lower risk of subclinical disease, treated prophylactically were included in the CTV2 volume. Planning target volume (PTV) was obtained by expansion of the CTVs to compensate for setup uncertainty, typically by 3-5 mm.
The PTV was adjusted appropriately, to respect the anatomical bounders located in close proximity to the target volumes. Briefly, 70.4 Gy in 32 fractions were prescribed to the PTVs of the gross disease (PTV70.4), 64 Gy in 32 fractions to the PTVs of high risk subclinical disease (subclinical disease at the surrounding area of the primary tumor and first echelon lymph nodes) (PTV64), and 57.6 in 32 fractions to the PTVs of the lesser risk sublicnical disease (the rest of the neck nodal targets) (PTV57.6), respectively. All patients in this group were treated with a simultaneous in-field boost IMRT technique. Inverse treatment planning was performed using the treatment planning system Eclipse v.8.10, anisotropic analytical algorithm (AAA). For each patient, a plan with 7-9 coplanar sliding-window IMRT beams of 6MV was generated. Table 1 . Several iterations were performed for optimization, aiming to reduce the mean dose to the larynx to the lowest possible, while maintaining the target coverage and the constraints to the other organs at risk according to the dose constraints and priority levels of the target volumes and organs at risk.
Dose-volume histograms
The dose-volume histograms (DVHs) of the target volumes and of the organs at risk were analyzed with the emphasis on the target volumes coverage and the laryngeal dose.
Statistical methods
A Wilcoxon sign rank test was employed to determine if there was a statistically significant difference between target coverage and laryngeal dose levels achieved for WF-IMRT versus J-IMRT technique. In this study p-values less than 0.05 were considered significant.
RESULTS
The averaged V100 for the PTV57. 
DISCUSSION
The use of IMRT has been shown to unnecessarily distribute higher dose of radiation to the larynx when the larynx sparing is not attempted as part of the IMRT treatment planning [5, 9, 10] .
To avoid this situation, Amdur et al. used a J-IMRT technique with a superior-neck IMRT matched with a conventional anterior lower neck field at the level of the thyroid notch, for patients with non-laryngeal head and neck cancer. Amdur et al. demonstrated that the dose to the normal larynx can be substantially reduced by shielding this organ on an anterior lower neck field [5] . For the WF-IMRT that included both the primary site and the upper and lower cervical lymph nodes, the mean laryngeal dose was 35 Gy in this study. This dose was much higher than the mean laryngeal dose of 17 Gy obtained when the normal larynx was shielded in the conventional anterior lower neck field by using a J-IMRT technique [5] . However, our study revealed that the mean laryngeal dose may be significantly reduced using WF-IMRT, when the larynx is defined as an organ at risk and is incorporated into the IMRT optimization process, without compromising the target volumes coverage or the accomplishment of dosimetric goals elsewhere in the treatment plan. The averaged mean laryngeal dose was 18 Gy using WF-IMRT, identical with the averaged mean laryngeal dose achieved with J-IMRT. Furthermore, the current study results suggest that laryngeal doses obtained by using WF-IMRT may be further reduced to values below 25 Gy previously reported in the literature [11] . Webster et al. demonstrated that the dose to the larynx was decreased significantly from a reported mean dose of approximately 45-50 Gy, usually described when larynx sparing is not attempted with WF-IMRT, to a mean dose of 25-40 Gy if the larynx is considered an organ at risk and is incorporated into the WF-IMRT optimization process [9] [10] [11] .
Studies evaluating the dose distribution close to the matchline between the opposed lateral fields and the anterior lower neck field as used by conventional radiotherapy for the treatment of non-laryngeal head and neck cancers showed that there may be a few millimeters of increased or decreased dose at or near field junction in the neck [12] . The clinical significance of these dosimetric findings remains unclear. Bubenzer et al. showed, using thermolaminescent dosimetry measurements on a Rando phantom, that the dose homogeneity along the matchline and critical structures are of concern if the upper head and neck fields were treated with IMRT and the lower neck with conventional (supraclavicular) fixed beam using a J-IMRT monoisocentric technique similar to the one employed in our study [13] . The averaged mean dose within the matchline volume were 69.3Gy for WF-MRT vs 66.2 Gy for J-IMRT (p=0.03) in the present study. Dose inhomogeneity across the matchline has been further investigated and new techniques to mitigate the matchline dosimetrical uncertainties have been explored and reported in the literature [14] [15] [16] . Amdur et al. reportedly move the upper border of the anterior lower neck field few millimeters superiorly at least once during the radiotherapy treatment, in order to reduce the dose inhomogeneity at the matchline between upper neck IMRT and conventional anterior lower neck field [14, 15] . Furthermore, a dynamic supraclavicular field-matching technique for head and neck cancer patients treated with IMRT has been developed by the same group [16] .
Conclusions
Taking in consideration the limitation of the present study including a small number of patients, our results suggest that the WF-IMRT technique may achieve an optimal coverage of the target volumes and mean dose to the larynx similar with J-IMRT, while avoiding the dosimetric uncertainty at the matchline present with J-IMRT. Clinical validation is required to determine whether this dosimetric benefit can be translated into meaningful clinical gains for oropharyngeal cancer patients. 
